Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years
- Written by PR Newswire
BAGSVÆRD, Denmark, March 26, 2021 /PRNewswire/ -- Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment of obesity in adolescents aged 12–17 years.1
Over the last 20 years, the global...
